Influence Of The Number Of Platelets And Hemoglobin Concentrations In Predicting The Development Of Proteinuria Induced By The Administration Of Bevacizumab
By: Vera Dabanovic
References
- 1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disesase. Nature Medicine 1995;1:27-31.
- 2. Jain RK, “Molecular Regulation of Vessel Maturation,” Nature Medicine 2003; 9:685-693.
- 3. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Department of Molecular Oncology. 2000; 55:15-35.
- 4. Dunst, J., Pigorsch, S., Hansgen, G., Hintner, I., Lautenschlager, C., Becker, A. Low hemoglobin is associated with increased levels of vascular endothelial growth factor (VEGF) in cancer patients. Does anemia stimulate angiogenesis? Strahlenther Onkologie.; 175: 93-96.
- 5. Gerber H, Condorelli F, Park J, Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. Journal of Biological Chemistry 1997; 272: 23659-67.
- 6. Katoh O, Tauchi H, Kawaishi K, Kimura A, Satow Y. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Research 1995; 55(23):5687-92.
- 7. Battinelli EM, Markens BA, Italiano JE. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiological and pathological angiogenesis. Blood. 2011;118(5):1359-69.
- 8. Carmeliet P., Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000; 407(6801): 249-57.
- 9. Poon RT-P, Fan S-T, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. Journal of Clinical Oncology 2001; 19(4): 1207–25.
- 10. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Medicine 2001; 7(9): 987-9.
- 11. FDA Approval for Bevacizumab. National Cancer Institute. (Accessed in May 2013 at)
- 12. SPC Avastin (Accessed in Sep 2012 at)
- 13. Abbate M, Zoja C, Remuzzi G. How Does Proteinuria Cause Progresive Renal Damage?2006; 17(11): 2974-84.
- 14. Loon NR. Diabetic Kidney Disease: Preventing Dialysis and Transplantation. Clinical Diabetes 2003; 21(2): 55-62.
- 15. Clinical Research Protocols. National Institutes of Health. (Accessed in June 2012 at)
- 16. Harshman LC, Kuo CJ, Wong BY, Vogelzang NJ, Srinivas S. Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma.. 2009 Oct; 27(8):851-6.
- 17. Mutlu H, Berk V, Karaca H, Erden A, Aslan T, Akca Z. Treatment Regimen With Bevacizumab Decreases Mean Platelet Volume in Patients With Metastatic Colon Cancer.and2012; 18 (5): 546-548.
- 18. DiLeo A, Messa C, Russo F, et al. Prognostic value of cytosolic estrogen receptors in human colorectal carcinoma and surrounding mucosa: preliminary results. Dig Dis Sci. 1994;39:2038-2042.
- 19. Heon Seo K, Lee HS, Jung B, et al. Estrogen Enhances Angiogenesis through a Pathway Involving Platelet-Activating Factor-Mediated Nuclear Factor-KB Activation.64, 2004; 6482-6488.
- 20. Witte D, Chirala M, Younes A, Li Y and Younes M: Estrogen receptor beta is expressed in human colorectal adenocarcinoma. Human Pathology 2001;32: 940-944.
- 21. Hendifar A, et al. Gender Disparities in Metastatic Colorectal Cancer Survival.2009; (15): 6391.
- 22. Schmetzer O, Flörcken A. Sex differences in the drug therapy for oncologic diseases.of Experimental. 2012;(214):411-42.
- 23. Wakelee HA, Dahlberg SE, Brahmer JR, et al.: Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. Lung Cancer 76, 2012;(3): 410-5.
- 24. Cassidy J, Saltz LB, Giantonio BJ, Kabbinavar FF, Hurwitz HI, Rohr UP. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. Journal of Cancer Research and Clinical Oncology 2010; 136(5): 737-743.
DOI: https://doi.org/10.1515/sjecr-2015-0019 | Journal eISSN: 2956-2090 (formerly 2335-075X, 2956-0454) | Journal ISSN: 2956-0454 (formerly 1820-8665)
Language: English
Page range: 143 - 150
Submitted on: Dec 16, 2013
Accepted on: Jan 10, 2014
Published on: Jun 27, 2015
Published by: University of Kragujevac, Faculty of Medical Sciences
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2015 Vera Dabanovic, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.